Rejuvenating sirtuins: the rise of a new family of cancer drug targets

Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional beh...

Full description

Saved in:
Bibliographic Details
Published inCurrent pharmaceutical design Vol. 19; no. 4; p. 614
Main Authors Bruzzone, Santina, Parenti, Marco Daniele, Grozio, Alessia, Ballestrero, Alberto, Bauer, Inga, Del Rio, Alberto, Nencioni, Alessio
Format Journal Article
LanguageEnglish
Published United Arab Emirates 01.02.2013
Subjects
Animals
Antineoplastic Agents - pharmacology
Drug Design
Drug Discovery - methods
Humans
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - pathology
Sirtuins - drug effects
Sirtuins - metabolism
Online AccessGet more information

Cover

More Information
Summary:Sirtuins are a family of NAD+-dependent enzymes that was proposed to control organismal life span about a decade ago. While such role of sirtuins is now debated, mounting evidence involves these enzymes in numerous physiological processes and disease conditions, including metabolism, nutritional behavior, circadian rhythm, but also inflammation and cancer. SIRT1, SIRT2, SIRT3, SIRT6, and SIRT7 have all been linked to carcinogenesis either as tumor suppressor or as cancer promoting proteins. Here, we review the biological rationale for the search of sirtuin inhibitors and activators for treating cancer and the experimental approaches to their identification.
ISSN:1873-4286
DOI:10.2174/138161213804581954